Private Advisor Group’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$327K Buy
8,383
+132
+2% +$4.26K ﹤0.01% 2059
2026
Q1
$268K Buy
8,251
+749
+10% +$24.1K ﹤0.01% 2265
2025
Q4
$264K Sell
7,502
-732
-9% -$25.9K ﹤0.01% 2243
2025
Q3
$216K Buy
8,234
+234
+3% +$6.98K ﹤0.01% 2289
2025
Q2
$212K Buy
+8,000
New +$211K ﹤0.01% 2198
2025
Q1
Sell
-6,526
Closed -$263K 2420
2024
Q4
$263K Sell
6,526
-2,560
-28% -$146K ﹤0.01% 1936
2024
Q3
$575K Buy
9,086
+3,625
+66% +$213K ﹤0.01% 1543
2024
Q2
$289K Buy
5,461
+958
+21% +$62.8K ﹤0.01% 1907
2024
Q1
$369K Buy
+4,503
New +$200K ﹤0.01% 1707
2020
Q3
Sell
-4,450
Closed -$32K 3364
2020
Q2
$32K Buy
+4,450
New +$29.5K ﹤0.01% 2326

Other funds holding VKTX

Private Advisor Group's VKTX Position: Q2 2026 in Review

Private Advisor Group increased its Viking Therapeutics (VKTX) stake by 1.6% in Q2 2026, buying an estimated $4.26K and bringing the position to 8,383 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #2059.

Private Advisor Group first reported a position in VKTX in Q2 2020 and has held it in 10 quarters since. The position peaked at $575K in Q3 2024. 112 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Private Advisor Group held 8,383 shares of Viking Therapeutics worth $327K as of Q2 2026.
  • Private Advisor Group bought 132 Viking Therapeutics shares in Q2 2026, an estimated $4.26K.
  • Viking Therapeutics made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #2059 holding.
  • Private Advisor Group first reported a position in Viking Therapeutics in Q2 2020 and has held it in 10 quarters since.
  • Private Advisor Group's Viking Therapeutics position peaked at $575K in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.